Halozyme Therapeutics’ (HALO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research note published on Tuesday morning, Benzinga reports. They currently have a $50.00 price objective on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on HALO. StockNews.com upgraded shares of Halozyme Therapeutics from a hold rating to a buy rating in a research note on Friday, February 23rd. JMP Securities reduced their price target on Halozyme Therapeutics from $72.00 to $71.00 and set a market outperform rating for the company in a research report on Wednesday, May 8th. Benchmark reissued a buy rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. Finally, TD Cowen began coverage on shares of Halozyme Therapeutics in a report on Thursday, February 29th. They set an outperform rating and a $54.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of Moderate Buy and an average target price of $53.14.

Halozyme Therapeutics Trading Up 12.7 %

NASDAQ HALO opened at $51.44 on Tuesday. The business’s fifty day moving average is $41.68 and its 200-day moving average is $39.24. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36. The stock has a market capitalization of $6.55 billion, a price-to-earnings ratio of 21.26, a PEG ratio of 0.50 and a beta of 1.28. Halozyme Therapeutics has a one year low of $32.78 and a one year high of $53.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.07. The business had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. Equities research analysts predict that Halozyme Therapeutics will post 3.44 EPS for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $45.38, for a total transaction of $453,800.00. Following the completion of the sale, the senior vice president now owns 168,176 shares of the company’s stock, valued at $7,631,826.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 30,000 shares of company stock valued at $1,255,100 in the last quarter. Corporate insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rise Advisors LLC bought a new stake in Halozyme Therapeutics in the first quarter valued at approximately $25,000. Whittier Trust Co. purchased a new position in shares of Halozyme Therapeutics in the first quarter worth $27,000. Principal Securities Inc. bought a new stake in Halozyme Therapeutics during the 4th quarter valued at $34,000. Fidelis Capital Partners LLC bought a new stake in Halozyme Therapeutics during the 1st quarter valued at $52,000. Finally, First Horizon Advisors Inc. boosted its position in Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 293 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.